Copyright
©The Author(s) 2019.
World J Clin Cases. Dec 26, 2019; 7(24): 4234-4244
Published online Dec 26, 2019. doi: 10.12998/wjcc.v7.i24.4234
Published online Dec 26, 2019. doi: 10.12998/wjcc.v7.i24.4234
Table 4 Multivariate analysis of progression-free and overall survival
| Variables | Overall survival | Progression-free survival | |||||
| HR | 95%CI | P value | HR | 95%CI | P value | ||
| IL-32 (pg/mL) | < 856.4/≥ 856.4 | 1.77 | 1.05-2.99 | 0.032 | 1.67 | 1.09-2.56 | 0.023 |
| ISS | I/II/III | 1.01 | 0.94-1.10 | 0.764 | 1.33 | 0.30-5.97 | 0.711 |
| DS | I/II/III | 1.5 | 0.58-3.91 | 0.407 | 1.02 | 0.99-1.06 | 0.242 |
| MRD | Negative/Positive | 3.64 | 1.06-12.5 | 0.044 | 1.68 | 1.20-2.35 | 0.003 |
- Citation: Wang G, Ning FY, Wang JH, Yan HM, Kong HW, Zhang YT, Shen Q. Expression of interleukin-32 in bone marrow of patients with myeloma and its prognostic significance. World J Clin Cases 2019; 7(24): 4234-4244
- URL: https://www.wjgnet.com/2307-8960/full/v7/i24/4234.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v7.i24.4234